成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

以色列Compugen
Compugen 成立于1993年，其宗旨是通過計算機技術同生物學和醫(yī)學的結合，發(fā)現(xiàn)和開發(fā)新藥。此公司的優(yōu)勢是具有雄厚的多學科基礎，其團隊由數(shù)學家、計算機學家、物理學家、化學家和分子生物學家組成，主要業(yè)務是用計算機技術分析和解釋生物學現(xiàn)象和數(shù)據(jù)，加速基因組學、蛋白質(zhì)組學和其他生物學數(shù)據(jù)的處理，研究基因組學、功能基因組學和蛋白質(zhì)組學，研發(fā)針對癌癥、免疫缺陷和神經(jīng)病的生物技術藥物、藥物靶點和診斷標記。

Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE: EVGN.TA) – to utilize the Company’s in silico predictive discovery capabilities in the agricultural biotechnology field. 

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.